Antidrug Antibodies in Patients Treated with Alirocumab
- PMID: 28304229
- DOI: 10.1056/NEJMc1616623
Antidrug Antibodies in Patients Treated with Alirocumab
Comment on
-
Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab.N Engl J Med. 2017 Apr 20;376(16):1517-1526. doi: 10.1056/NEJMoa1614062. Epub 2017 Mar 17. N Engl J Med. 2017. PMID: 28304227 Clinical Trial.
Similar articles
-
Alirocumab as Add-On to Atorvastatin Versus Other Lipid Treatment Strategies: ODYSSEY OPTIONS I Randomized Trial.J Clin Endocrinol Metab. 2015 Aug;100(8):3140-8. doi: 10.1210/jc.2015-1520. Epub 2015 Jun 1. J Clin Endocrinol Metab. 2015. PMID: 26030325 Free PMC article. Clinical Trial.
-
Efficacy and Safety of Alirocumab Versus Ezetimibe Over 2 Years (from ODYSSEY COMBO II).Am J Cardiol. 2017 Sep 15;120(6):931-939. doi: 10.1016/j.amjcard.2017.06.023. Epub 2017 Jun 28. Am J Cardiol. 2017. PMID: 28750828 Clinical Trial.
-
Therapeutic Potential and Critical Analysis of the PCSK9 Monoclonal Antibodies Evolocumab and Alirocumab.Ann Pharmacother. 2015 Dec;49(12):1327-35. doi: 10.1177/1060028015608487. Epub 2015 Sep 30. Ann Pharmacother. 2015. PMID: 26424774 Review.
-
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia.Eur Heart J. 2015 Nov 14;36(43):2996-3003. doi: 10.1093/eurheartj/ehv370. Epub 2015 Sep 1. Eur Heart J. 2015. PMID: 26330422 Free PMC article. Clinical Trial.
-
Evaluation of the Potential Role of Alirocumab in the Management of Hypercholesterolemia in Patients with High-Risk Cardiovascular Disease.Pharmacotherapy. 2015 Aug;35(8):771-9. doi: 10.1002/phar.1621. Epub 2015 Aug 8. Pharmacotherapy. 2015. PMID: 26256279 Review.
Cited by
-
Efficacy and Safety of Evolocumab and Alirocumab as PCSK9 Inhibitors in Pediatric Patients with Familial Hypercholesterolemia: A Systematic Review and Meta-Analysis.Medicina (Kaunas). 2024 Oct 8;60(10):1646. doi: 10.3390/medicina60101646. Medicina (Kaunas). 2024. PMID: 39459433 Free PMC article. Review.
-
Safety of the PCSK9 inhibitor alirocumab: insights from 47 296 patient-years of observation.Eur Heart J Cardiovasc Pharmacother. 2024 Jul 16;10(4):342-352. doi: 10.1093/ehjcvp/pvae025. Eur Heart J Cardiovasc Pharmacother. 2024. PMID: 38658193 Free PMC article. Review.
-
Inclisiran-A Revolutionary Addition to a Cholesterol-Lowering Therapy.Int J Mol Sci. 2023 Apr 6;24(7):6858. doi: 10.3390/ijms24076858. Int J Mol Sci. 2023. PMID: 37047830 Free PMC article. Review.
-
Generalized additive models to analyze nonlinear trends in biomedical longitudinal data using R: Beyond repeated measures ANOVA and linear mixed models.Stat Med. 2022 Sep 20;41(21):4266-4283. doi: 10.1002/sim.9505. Epub 2022 Jul 7. Stat Med. 2022. PMID: 35796389 Free PMC article.
-
Unusual responses to PCSK9 inhibitors in a clinical cohort utilizing a structured follow-up protocol.Am J Prev Cardiol. 2020 May 1;1:100012. doi: 10.1016/j.ajpc.2020.100012. eCollection 2020 Mar. Am J Prev Cardiol. 2020. PMID: 34327453 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
